Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Amylyx Pharmaceuticals is a clinical-stage biotechnology company that previously commercialized Relyvrio (AMX0035) for ALS treatment but voluntarily withdrew the drug in April 2024 after Phase 3 PHOENIX trial failed to meet primary endpoint. The company is now pivoting to develop AMX0114 (a novel ROCK2 inhibitor) for neurodegenerative diseases and faces significant execution risk as a pre-revenue biotech rebuilding its pipeline with approximately $170M cash runway.
Amylyx operates a high-risk, binary-outcome biotech model focused on developing novel therapeutics for neurodegenerative diseases. The company previously generated revenue through Relyvrio sales in US and Canada but lost this revenue stream after voluntary withdrawal. Future monetization depends entirely on advancing AMX0114 through clinical trials (currently Phase 1/2), achieving regulatory approval (earliest 2028-2030 timeline), and successfully commercializing in competitive ALS/neurodegenerative markets. Pricing power would be substantial if approved given rare disease dynamics, but probability-adjusted NPV is highly uncertain. The company has no manufacturing infrastructure and would rely on CMO partnerships.
AMX0114 clinical trial data readouts and regulatory milestone achievements (Phase 1/2 safety/efficacy signals)
Partnership or licensing deals that validate AMX0114 platform and provide non-dilutive funding
Cash runway updates and equity financing announcements (dilution risk given negative FCF)
Competitive developments in ALS/neurodegenerative space (Biogen, Mitsubishi Tanabe, Ionis programs)
FDA regulatory pathway clarity for ROCK2 inhibitor mechanism and potential accelerated approval eligibility
Binary clinical trial risk - single-asset company with AMX0114 success determining survival; Phase 2/3 failure would likely result in wind-down or acquisition at distressed valuation
Regulatory pathway uncertainty for novel ROCK2 inhibitor mechanism with no approved precedents in neurodegenerative diseases
Competitive intensity in ALS therapeutics with multiple well-funded programs (Biogen/Ionis tofersen, Mitsubishi edaravone, emerging gene therapies) potentially limiting market opportunity
Reputational overhang from Relyvrio withdrawal may create FDA scrutiny and investor skepticism on future programs
Larger biotechs (Biogen, Sarepta, Vertex) with superior capital resources and established neurology commercial infrastructure could out-execute on similar mechanisms
Academic research advancing alternative ALS targets (TDP-43, C9orf72) could render ROCK2 inhibition obsolete before approval
Difficulty recruiting clinical trials in small ALS patient population with multiple competing studies
Cash runway risk - estimated 2-3 years of funding at current burn rate requires additional financing before potential revenue generation
Equity dilution risk from future capital raises given pre-revenue status and negative operating cash flow of $200M TTM
No debt cushion or credit facilities disclosed, making company entirely dependent on equity markets for survival
Minimal tangible assets (13.70 current ratio suggests mostly cash/securities) provide limited liquidation value if pipeline fails
low - Clinical-stage biotech operations are largely insulated from GDP fluctuations as R&D spending is driven by clinical milestones rather than economic conditions. However, capital markets access for financing is cyclical, with biotech IPO/follow-on windows tightening during recessions. Patient enrollment can be marginally affected by healthcare utilization patterns during severe downturns.
Rising interest rates negatively impact valuation through higher discount rates applied to distant cash flows (8-10+ years for potential commercialization). Higher rates also reduce appetite for speculative growth assets and increase competition from risk-free alternatives. Amylyx holds significant cash balances that benefit from higher short-term rates (estimated $170M earning 4-5% vs 0% in 2021), partially offsetting valuation compression. Debt financing is minimal (0.02 D/E) so direct interest expense impact is negligible.
Minimal - Company has negligible debt and operates with equity financing model. Credit conditions affect ability to raise capital through convertible debt or venture debt facilities, but primary funding mechanism is equity markets. Tighter credit could force more dilutive equity raises if biotech financing windows close.
momentum/speculative - Stock exhibits extreme volatility (296.9% 1-year return, 76.6% 6-month) attracting biotech specialists, event-driven traders, and retail momentum players betting on clinical catalysts. The 1.1% 3-month return vs 76.6% 6-month suggests recent consolidation after major move. Not suitable for value investors given negative earnings and pre-revenue status. No dividend. Institutional ownership likely concentrated among specialized healthcare funds willing to accept binary risk/reward.
high - Clinical-stage single-asset biotechs exhibit 60-100% annualized volatility driven by binary clinical/regulatory events. Recent 296.9% annual return demonstrates extreme price swings. Negative operating margin of -360.2% and cash burn create existential risk. Options market likely prices high implied volatility around data catalyst dates. Beta to broader market likely low, but idiosyncratic risk is extreme.
